Ex Vivo News and Research

RSS

Aethlon Hemopurifier can capture Nef protein exosomes linked with HIV

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome.

14 Dec 2011

Plexxikon announces scientific findings from PLX3397 preclinical studies on AML

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced scientific findings from preclinical studies showing that treatment with a novel oral agent, PLX3397, selectively inhibited key cancer-driving Flt3 mutations that occur in 20-30 percent of acute myeloid leukemia (AML) patients.

13 Dec 2011

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Hematopoietic cell transplantation (HCT), the transplantation of blood-forming stem cells from the bone marrow, peripheral blood, or umbilical cord blood, is the primary option for treatment for many patients who suffer from various hematologic disorders, including blood cancers, sickle cell disease, bone marrow deficiencies, bleeding disorders, and autoimmune disorders. Research investigating breakthroughs in hematopoietic cell transplantation will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

New cancer research findings presented at 53rd ASH annual meeting

Researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine presented new research findings in 25 presentations this weekend at the 53rd Annual Meeting of the American Society of Hematology (ASH) at the San Diego Convention Center.

12 Dec 2011

Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California.

7 Dec 2011

Taconic and Oncodesign announce agreement to co-promote and co-develop solutions to advance oncology research

Taconic, a leading provider of life sciences solutions, and Oncodesign(R), an innovative leader in the discovery of novel anti-cancer therapies, announce today that they have entered into an agreement to co-develop and co-promote pre-clinical oncology in vivo solutions for researchers worldwide. The agreement provides researchers with improved access to a large, diverse portfolio of translational models for use in pre-clinical oncology studies, along with supporting scientific services.

24 Oct 2011

Roche's gantenerumab removes amyloid plaques from the brain of patients with AD

Roche today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease. The study "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab" is published today in the October issue of Archives in Neurology.

11 Oct 2011

Gantenerumab appears to reduce brain amyloid levels in patients with AD

Although it is a small study and more clinical trials are needed, treatment with the medication gantenerumab appeared to result in a reduction in brain amyloid levels in patients with Alzheimer disease, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.

11 Oct 2011

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

University of Maryland surgeons transplant first lungs treated with experimental repair process

Surgeons at the University of Maryland Medical Center have transplanted the first lungs treated in the United States with an experimental repair process before transplantation. The procedure is part of a five-center national clinical research trial to evaluate the efficacy of repairing, before transplant, lungs that might otherwise have been passed over as unsuitable for organ donation.

8 Sep 2011

Sarcoma Oncology Center, Aethlon Medical to study ex vivo effectiveness of Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.

24 Aug 2011

First North American clinical trial to test adult MSC transplantation as a new MS therapy

A team of researchers at three landmark Cleveland institutions have come together to launch a new clinical trial of an experimental treatment for multiple sclerosis.

24 Aug 2011

Researchers identify novel sensory pathway that modulates pro-inflammatory cells

New research led by Derya Unutmaz, MD associate professor, the Departments of Pathology, Medicine, and Microbiology at NYU School of Medicine and Mark Sundrud, PhD, of Tempero Pharmaceuticals, Inc., has identified a novel sensory pathway that modulates the potency of Th17 cell responses.

11 Aug 2011

Researchers helps explain how the adult brain cleans out dead brain cells and produces new ones

Adult brains generate thousands of new brain cells called neurons each day; however only a small fraction of them survive. The rest die and are consumed by scavenger cells called phagocytes. Until now, scientists have not fully understood how this process works, which phagocytes are unique in the brain, and how the removal of dead neurons influences the production of new neurons.

10 Aug 2011

Glenmark commences Revamilast Phase IIb trial in chronic inflammatory disorders

Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.

10 Aug 2011

BioWa, arGEN-X sign license agreement for POTELLIGENT Technology

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.

26 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

IOTA NanoSolutions secures funding for commercialisation of ContraSol technology

IOTA NanoSolutions Limited, a specialist formulation company, is pleased to announce today that it has completed a financing round to support the commercialisation of its proprietary nanodispersion formation technology, ContraSol™. New investor, QIB(UK) Plc joins Unilever Ventures Limited (UV) in this financing round.

28 Jun 2011

In vivo genome editing restores hemostasis in mouse model of blood clotting disorder

Using an innovative gene therapy technique called genome editing that hones in on the precise location of mutated DNA, scientists have treated the blood clotting disorder hemophilia in mice.

27 Jun 2011

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present the Aethlon ADAPT™ system in a presentation at the C21 BioVentures™ Life Sciences Partnering Conference.

23 May 2011